RxDoctor Payments Data

Paul Laflam, MD

Nephrology · Christiansburg, VANPI 1871522730

Payments from drug & device makers

$1,887in general payments, 2019–2025

Across 86 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$415
  • Ardelyx, Inc.$206
  • Otsuka America Pharmaceutical, Inc.$172
  • Akebia Therapeutics Inc$152
  • Amgen$137
  • Travere Therapeutics, Inc.$137
  • plus $669 from 10 others

What the payments were for

  • Food & beverage$1,75693%
  • Education$1317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,887 in reported general payments places this provider in the 60th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$171,728
Medicare patients
519
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl54$294,473
FarxigaDapagliflozin Propanediol133$94,267
AuryxiaFerric Citrate27$41,806
MounjaroTirzepatide33$32,688
JardianceEmpagliflozin38$28,944
LokelmaSodium Zirconium Cyclosilicate18$22,628
Sevelamer Carbonate147$18,352
JanuviaSitagliptin Phosphate18$15,164
EliquisApixaban17$13,914
Midodrine Hcl54$10,505
OzempicSemaglutide11$10,168
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt13$8,038
Bumetanide117$4,880
Calcitriol300$3,367
Dofetilide12$3,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$415$116,895151 claims
Akebia Therapeutics IncAuryxia$152$41,80627 claims
Boehringer IngelheimJardiance$26$28,94438 claims
Novo NordiskOzempic$108$10,16811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 298 nephrology providers in Virginia.

Other nephrology in Christiansburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →